Department of Psychiatry, School of Medicine, Yale University, 300 George Street, Suite 901, New Haven, CT 06511, USA.
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, USA.
Psychiatr Clin North Am. 2023 Jun;46(2):291-305. doi: 10.1016/j.psc.2023.02.004. Epub 2023 Mar 25.
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also recognition that psychedelic research may be subject to a "hype bubble" at the present time. Future studies focused on delineating necessary ingredients of psychedelic treatments and the neurobiological basis of their effects, will help pave the way for the clinical use of these compounds.
人们越来越感兴趣地探索迷幻剂在治疗抵抗性抑郁症（TRD）中的治疗潜力。经典迷幻剂（如裸盖菇素、LSD、卡他碱/二甲基色胺）和非典型迷幻剂（如氯胺酮）已在 TRD 中进行了研究。目前，经典迷幻剂治疗 TRD 的证据有限；然而，早期研究显示出有希望的结果。人们也认识到，迷幻药研究目前可能受到“炒作泡沫”的影响。未来的研究集中于描绘迷幻药治疗的必要成分和它们的作用的神经生物学基础，将有助于为这些化合物的临床应用铺平道路。
